ETHOS

𝗚𝗟𝗣-𝟭 𝗗𝗿𝘂𝗴𝘀 𝗠𝗮𝘆 𝗗𝗼 𝗠𝗼𝗿𝗲 𝗧𝗵𝗮𝗻 𝗧𝗿𝗲𝗮𝘁 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗮𝗻𝗱 𝗢𝗯𝗲𝘀𝗶𝘁𝘆: 𝗡𝗲𝘄 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀 𝗶𝗻 𝗦𝗰𝗵𝗶𝘇𝗼𝗽𝗵𝗿𝗲𝗻𝗶𝗮 A major study in The Lancet Psychiatry (November 2026) suggests that GLP-1–based medications, including semaglutide (Ozempic/Wegovy), may be associated with fewer psychiatric hospitalizations and emergency visits among patients with schizophrenia. Researchers analyzed electronic health records of 70,257 adults across all 50 US states with schizophrenia and type 2 diabetes. Key Findings: Compared with patients who did not initiate GLP-1 therapy, those who started treatment had: - 24% lower relative hazard of psychiatric hospitalization. - 29% lower relative hazard of psychiatric emergency department visits. - Lower psychiatric acute-care use even when compared with patients starting other diabetes medications (DPP-4 and SGLT2 inhibitors). - Among patients taking antipsychotics, an estimated 1-year number needed to treat (NNT) of 32 to avert one psychiatric hospitalization or ED visit. This is an observational estimate, not proof of treatment benefit. - Favorable associations were particularly observed with semaglutide, liraglutide, and tirzepatide. Interestingly, the association was strongest among patients who lost weight, but was also present in some patients whose weight remained stable. This raises questions about potential effects beyond weight loss, including inflammation, insulin signaling, and brain pathways involved in dopamine regulation. My Take as a Psychiatrist: Patients with schizophrenia face a disproportionate burden of obesity, diabetes, cardiovascular disease, and premature mortality, partly related to antipsychotic-associated metabolic complications. GLP-1 therapies already offer important metabolic benefits. The possibility that they may also be associated with improved psychiatric stability is particularly exciting. However, this was an observational study. It cannot establish causation, and differences in patient characteristics or health care access may partly explain the findings. GLP-1 medications are NOT established treatments for schizophrenia and should not replace antipsychotics. But these findings strengthen the case for integrating metabolic and psychiatric care rather than treating them as separate problems. "Treating metabolic disease in schizophrenia may have benefits extending far beyond blood sugar and body weight." Randomized controlled trials are the essential next step. Source: Davoodian N, et al. The Lancet Psychiatry, November 2026. Observational cohort study of 70,257 US adults. thelancet.com/journals/lanps… #Psychiatry #Schizophrenia #GLP1 #Ozempic #Semaglutide #MentalHealth #Diabetes

MO, the only peptide you need for hair regrowth is GHK-cu. But, if you’re afraid GHK-Cu will lower your DHT, you should be terrified of liver and oysters. It’s the copper that inhibits 5AR, not the peptide. 2mg GHK-Cu: ~0.3mg copper 1 slice of liver: ~10mg copper 100g of oysters: ~7.6mg copper That’s 30x more copper from a bit of liver. And dietary copper doesn’t come close to the levels needed to block 5AR in your body.

Lab-tested GLP brands: - Eli Lilly Zepbound, listed via Ro: metals below detection - Umbrella Labs retatrutide: 4.7/5 mg labeled potency - Limitless Biotech semaglutide: metals below detection - Evolve Peptides semaglutide: 99.91% chromatographic purity - Prime Peptides semaglutide: 5.51 mg measured versus 5 mg labeled - Paramount Peptides semaglutide: over 100% potency - Coastal Peptides semaglutide: identity test failed - Peptide Gurus retatrutide: identity test failed For Lilly and Limitless, arsenic, cadmium and lead were below 0.01 µg/g; mercury was below 0.005 µg/g Specific samples from 2025–2026, not a safety ranking. Research products are not interchangeable with prescription medicines. Complete peptide reports on Oasis app

🇺🇸 Chinese chemical companies linked to fentanyl production are now selling black-market “looksmaxxing” peptides to Americans. Some suppliers are marketing unapproved substances for weight loss, muscle growth, and improving physical appearance. The FDA has warned about the dangers of unapproved injectable peptides, while blockchain researchers estimate the underground market has grown into a business exceeding $100 million annually.

The next generation of GLP-1 drugs might not even be peptides. Lilly's orforglipron is a non-peptide pill that activates the GLP-1 receptor. In 1,698 people, it led to 9.2% weight loss vs. 5.3% with oral semaglutide at 52 weeks. And unlike oral semaglutide, it can be taken without fasting.

We will continue to get more and more human data about BPC-157. In this study 16 human patients with knee pain got BPC-157 injection, the recovery rates on BPC are as you probably expect.

The pivotal TRIUMPH-1 trial demonstrated an average weight loss of 28.3% of body weight at 80 weeks with the highest studied dose of retatrutide, reaching levels historically associated with bariatric surgery. However, as these potent therapies advance toward potential regulatory review, obesity medicine specialists face an emerging clinical reality: Many prospective candidates will not be starting treatment from scratch. Many may arrive to retatrutide therapy having already optimized semaglutide or tirzepatide. Some may be facing the challenge that clinicians are increasingly describing — the GLP-1 plateau. mdsc.pe/4eJ7Nyh

Peptide ER visits in NSW, Australia: 5 a month to 217+ a month - July 2025: 5 - Sept 2026: 217+ - Total since July 2025: 1,180 - Retatrutide in 833 BPC-157, TB-500, GHK-Cu, CJC-1295, retatrutide all named. None approved in Australia Source: NSW Health surveillance data

There is now a National recall of GLP-1 drug (tirzepatide) made by a US compounding pharmacy because it puts patients at risk! Please be careful! Tell your children who maybe taking these without your knowledge.

GLP-1 peptides protect the gut from immune injury. Essential role of endogenous GLP-1 family peptides to reduce inflammation and restore mucosal integrity in the experimental model @DanielJDrucker @CellRepMed cell.com/cell-reports-medici…